Table 2 KEGG pathway enrichment for the genes in the coexpression modules
Module | Term | Count | % | PValue |
|---|---|---|---|---|
M1 | hsa03010:Ribosome | 55 | 2.98 | 5.82E-18 |
hsa04144:Endocytosis | 53 | 2.87 | 2.69E-06 | |
hsa05016:Huntington’s disease | 48 | 2.60 | 1.8E-07 | |
hsa05012:Parkinson’s disease | 47 | 2.54 | 1.18E-11 | |
hsa00190:Oxidative phosphorylation | 44 | 2.38 | 6.04E-11 | |
M2 | hsa05016:Huntington’s disease | 31 | 3.78 | 6.94E-08 |
hsa03010:Ribosome | 29 | 3.54 | 3.32E-10 | |
hsa05012:Parkinson’s disease | 27 | 3.29 | 1.97E-08 | |
hsa05010:Alzheimer’s disease | 26 | 3.17 | 2.25E-06 | |
hsa00190:Oxidative phosphorylation | 24 | 2.93 | 3.91E-07 | |
M3 | hsa04145:Phagosome | 17 | 5.47 | 2.48E-07 |
hsa05168:Herpes simplex infection | 16 | 5.14 | 1.63E-05 | |
hsa04144:Endocytosis | 14 | 4.50 | 0.003325 | |
hsa04142:Lysosome | 13 | 4.18 | 1.79E-05 | |
hsa04141:Protein processing in endoplasmic reticulum | 13 | 4.18 | 0.000453 | |
M4 | hsa04380:Osteoclast differentiation | 19 | 6.29 | 3.23E-10 |
hsa05152:Tuberculosis | 16 | 5.30 | 6.22E-06 | |
hsa04145:Phagosome | 15 | 4.97 | 4.18E-06 | |
hsa05140:Leishmaniasis | 13 | 4.30 | 3.15E-08 | |
hsa05164:Influenza A | 13 | 4.30 | 0.00039 | |
M6 | hsa04010:MAPK signaling pathway | 7 | 4.27 | 0.027535 |
hsa03040:Spliceosome | 6 | 3.66 | 0.007182 | |
hsa05164:Influenza A | 6 | 3.66 | 0.021085 | |
hsa04015:Rap1 signaling pathway | 6 | 3.66 | 0.04254 | |
hsa00310:Lysine degradation | 5 | 3.05 | 0.001245 | |
M7 | hsa05200:Pathways in cancer | 11 | 7.01 | 0.00439 |
hsa05152:Tuberculosis | 9 | 5.73 | 0.000293 | |
hsa04071:Sphingolipid signaling pathway | 7 | 4.46 | 0.001042 | |
hsa05161:Hepatitis B | 7 | 4.46 | 0.002742 | |
hsa04650:Natural killer cell mediated cytotoxicity | 6 | 3.82 | 0.006497 | |
M8 | hsa05162:Measles | 13 | 8.33 | 5.71E-09 |
hsa05164:Influenza A | 12 | 7.69 | 1.01E-06 | |
hsa05168:Herpes simplex infection | 11 | 7.05 | 1.21E-05 | |
hsa05160:Hepatitis C | 10 | 6.41 | 6.11E-06 | |
hsa04978:Mineral absorption | 6 | 3.85 | 7.03E-05 |